Atopic dermatitis

Atopic dermatitis

Atopic dermatitis (AD) often begins in infancy and affects up to 25% of children. Topical steroids are often the treatment of choice for inflammatory skin diseases like AD, but they come with unwanted side effects. Current non-steroidal drugs typically use a single or dual-target approach, resulting in suboptimal efficacy. Itch Is the most prevalent, severe, and burdensome symptom of AD.

DB-007-5 targets a wide array of pathways overactive in AD. In repeated trials using a well-established animal model of human AD, DB-007-5 exhibited significant inhibitory effects in both disease score and itch. DB-007-5 is well-tolerated by skin.